ALK and non-small cell lung carcinoma: Identification of rearrangements in anaplastic lymphoma kinase (<i>ALK</i>) gene is an effective instrument for more effective targeted therapy of NSCLC using ALK inhibitors dramatically raising progression-free survival in the <i>ALK-</i>mutated group of patients.